Gennari Luigi
University of Siena, Department of Internal Medicine, Endocrine-Metabolic Sciences and Biochemistry, Policlinico Le Scotte, Siena, Italy.
Curr Opin Investig Drugs. 2005 Oct;6(10):1067-78.
Pfizer is developing lasofoxifene, an oral naphthalene derivative selective estrogen receptor modulator identified under a collaboration with Ligand, for the treatment of osteoporosis and vaginal atrophy. In August 2004, Pfizer submitted a New Drug Application to the Food and Drug Administration (FDA) seeking approval of lasofoxifene for the treatment of osteoporosis; however, in September 2005, the FDA issued a non-approvable letter.
辉瑞公司正在研发拉索昔芬，这是一种口服萘衍生物选择性雌激素受体调节剂，是与Ligand公司合作确定的，用于治疗骨质疏松症和阴道萎缩。2004年8月，辉瑞公司向美国食品药品监督管理局（FDA）提交了一份新药申请，寻求批准拉索昔芬用于治疗骨质疏松症；然而，2005年9月，FDA发出了一封不批准函。
